Generics

Filter

Current filters:

None

Popular Filters

55 to 79 of 1235 results

Novartis patent settlement on Gleevec with Sun Pharma subsidiary

15-05-2014

The US unit of Swiss drug major Novartis has settled its litigation with the US subsidiary of India’s…

GenericsGleevecNovartisOncologyPatentsSun Pharmaceutical IndustriesUSA

Biocad’s AcellBia is first MAb biosimilar approved by Russia’s Ministry of Health

15-05-2014

A biosimilar of Swiss drug major Roche’s MabThera (rituximab), to be marketed under the trade name…

AcellBiaBiocadBiosimilarsGenericsMabTheraOncologyRegulationRocheRussia

Novasep commissions 4 million-euro plant extension for commercial ADC payload manufacturing

15-05-2014

French ingredients company Novasep says that its 4 million-euro ($5.5 million) investment to expand its…

FranceGenericsNovasepOncologyProduction

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

14-05-2014

US generic drugmaker Mylan says it has launched Olanzapine Orally Disintegrating tablets (ODT), 5mg,…

ActavisEli LillyExalgoGenericsMallinckrodtMarkets & MarketingMylanNeurologicalRegulationUSAZyprexa

Fresenius Kabi expands IV drug business in Latin America with buy of Novafarma

Fresenius Kabi expands IV drug business in Latin America with buy of Novafarma

13-05-2014

Germany-based Fresenius Kabi has entered into an agreement to acquire the privately held Brazilian pharmaceutical…

BrazilFresenius KabiGenericsMergers & AcquisitionsNovafarma Industria Farmaceutica

Akorn to acquire VersaPharm for $440 million

Akorn to acquire VersaPharm for $440 million

10-05-2014

Following swiftly on its completion of the acquisition of Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million…

AkornDermatologicalsGenericsMergers & AcquisitionsVersaPharm

Vivus says Actavis has filed ANDA for generic Qsymia

Vivus says Actavis has filed ANDA for generic Qsymia

10-05-2014

US drug developer Vivus disclosed on Friday that the company had received notice from generics major…

ActavisGenericsMetabolicsPatentsQsymiaRegulationUSAVivus

Actavis debuts generic copy of Catapres-TTS

Actavis debuts generic copy of Catapres-TTS

08-05-2014

Ireland-headquartered generics major Actavis has launched a generic version of German family-owned pharma…

ActavisBoehringer IngelheimCardio-vascularCatapres-TTSGenericsMarkets & MarketingUSA

Grunenthal strengthens pain product portfolio with European rights to etoricoxib

07-05-2014

Family-owned German drugmaker Grunenthal Group today announced the signing of an exclusive promotion…

etoricoxibEuropeGenericsGrunenthalLicensingMerck & CoNeurological

Australian Audit Commission’s “nuclear option to attack the PBS is madness”

Australian Audit Commission’s “nuclear option to attack the PBS is madness”

05-05-2014

The Australian National Commission of Audit’s complete dismantling and destruction of the Pharmaceutical…

AustraliaFinancialGenericsHealthcarePolitics

Sun Pharma vows “appropriate action” as Ranbaxy merger halted

05-05-2014

In the wake of a suspension of its proposed $4 billion acquisition of domestic rival Ranbaxy Laboratories…

GenericsIndiaMergers & AcquisitionsProductionRanbaxy LaboratoriesSun Pharmaceutical IndustriesUSA

FTC Amicus Brief urges Court of Appeals to reverse DC ‘No-Authorized Generic’ commitments ruling

03-05-2014

The US Federal Trade Commission filed an Amicus Brief in the US Court of Appeals for the Third Circuit,…

ActavisGenericsLamictalLegalPatentsUSA

Teva 1st-qtr 2014 boosted by new generics

Teva 1st-qtr 2014 boosted by new generics

01-05-2014

Israel generic giant Teva Pharmaceutical Industries reported a 2% rise in revenues to $5.0 billion for…

FinancialGenericsTeva Pharmaceutical Industries

Mylan 1st-qtr 2014 revenues miss analysts’ expectations

Mylan 1st-qtr 2014 revenues miss analysts’ expectations

01-05-2014

US generic drugmaker Mylan reported first-quarter 2014 results before markets opened, posting adjusted…

FinancialGenericsMylan

Actavis swings into profit as 1st-qtr 2014 sales leap 40%

Actavis swings into profit as 1st-qtr 2014 sales leap 40%

30-04-2014

Ireland headquartered generics giant Actavis saw its shares rise 2.6% to $203 in mid-morning trading,…

ActavisFinancialGenerics

EU approval for Teva’s DuoResp Spiromax for asthma and COPD

EU approval for Teva’s DuoResp Spiromax for asthma and COPD

30-04-2014

The European Commission has granted marketing authorization for Israel-based Teva Pharmaceutical Industries’…

DuoResp SpiromaxEuropeGenericsRegulationRespiratory and PulmonaryTeva Pharmaceutical Industries

Endo to buy Mexican specialty pharma company Somar

29-04-2014

USA-based Endo International as entered into a definitive agreement to acquire Grupo Farmaceutico Somar,…

Endo PharmaceuticalsGenericsMergers & AcquisitionsMexicoSouth America

Mylan challenges FDA ruling on exclusivity relating to generic celecoxib

Mylan challenges FDA ruling on exclusivity relating to generic celecoxib

27-04-2014

US generics firm Mylan has filed suit against the US Food and Drug Administration, challenging the agency's…

CelebrexGenericsInflammatory diseasesLegalMylanPatentsPfizer

Actavis settles Celebrex patent challenge with Pfizer

24-04-2014

Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…

ActavisAnti-Arthritics/RheumaticsCelebrexGenericsLegalPatentsPfizerUSA

Abbott may acquire one of Russia’s leading drugmakers for $240 million

23-04-2014

The USA’s Abbott Laboratories is considering acquiring the 81.1 % stake in Veropharm, one of Russia’s…

Abbott LaboratoriesGenericsMergers & AcquisitionsRussiaVeropharm

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

55 to 79 of 1235 results

Back to top